Brian T. McLaughlin

Brian McLaughlin practices at UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center.

Brian McLaughlin's NPI, 1174719512, was assigned on September 19, 2007. Brian McLaughlin graduated from State University of New York at Stony Brook, School of Medicine in 2006. Brian McLaughlin holds Pennsylvania license MD437105.

Brian McLaughlin's primary practice is UPMC Magee-Womens Hospital, at 300 Halket Street, Pittsburgh, PA 15213 in Allegheny County. The practice phone is (412) 641-4010.

Brian McLaughlin's primary practice is UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center. Brian McLaughlin is also affiliated with UPMC Presbyterian. The medical group on file is UPMC Hillman Cancer Center. Dmand AI also links Brian McLaughlin to 3 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Brian McLaughlin practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Brian McLaughlin's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Brian McLaughlin is board certified in hematology by the American Board of Internal Medicine. Brian McLaughlin is licensed in Pennsylvania.

CMS data shows 1,324 Medicare services from Brian McLaughlin across 9 procedure codes in 2024, for 327 Medicare patients. Medicare paid $90,352 for them.

CMS counts 327 Medicare patients who saw Brian McLaughlin in 2024. The largest group is 65 to 74, with 155 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Brian McLaughlin's median patient age at 74, with 48% women.

In 2024, Brian McLaughlin wrote 1,512 Medicare Part D claims for 242 patients. 70% of them were for generic drugs. CMS names the drug for 1,317 of them, across 33 drugs with 11 or more claims each, at $4,368,197 in total drug cost. In 2023, CMS named 1,331 claims across 33 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 65 out of 100 for Brian McLaughlin for performance year 2024, reported as part of a group. Brian McLaughlin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 5 papers to Brian McLaughlin, published from 2012 to 2024. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Etoposide and Leukemia, Myeloid, Acute. Brian McLaughlin's most frequent co-authors are Mounzer E. Agha, MD, Annie Pearl Im, MD and Anastasios Raptis.

Dmand AI links Brian McLaughlin to 1 clinical trial. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 17 general payments to Brian McLaughlin from 10 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 59% of the total. Merck Sharp & Dohme Corporation paid the most, $515.

Brian McLaughlin graduated from State University of New York at Stony Brook, School of Medicine in 2006.